Introduction
============

3-keto-dihydrosphingosine reductase (KDSR) is an early, essential enzyme in the pathway of *de novo* sphingolipid synthesis that catalyzes the conversion of 3-keto-dihydrosphingosine (KDS) to dihydrosphingosine (DHS) on the cytosolic leaflet of the endoplasmic reticulum.^[@b1-1041036]^ The canonical transcript for *KDSR* encodes a 332 amino acid protein. The gene is widely transcribed,^[@b1-1041036]--[@b3-1041036]^ consistent with the integral roles of the sphingolipid family in forming lipid rafts that facilitate membrane trafficking and in the regulation of fundamental cellular functions that include apoptosis, differentiation, and proliferation.^[@b4-1041036]^ The importance of sphingolipid synthesis for normal cellular functions is illustrated by the complex multisystem phenotypes of null mice for key enzymes or receptors in the pathway, including defective platelet activation and thrombus formation.^[@b5-1041036],[@b6-1041036]^ A pathway for *de novo* synthesis of sphingolipids in a megakaryocytic cell line has been shown, but this plays a minimal role in mature platelets, which instead acquire essential sphingolipids by incorporating them from plasma or recycling plasma membrane sphingomyelins, both largely independently of KDSR.^[@b7-1041036]^

Consistent with these important roles of sphingolipids, compound heterozygous variants in *KDSR* ([Figure 1](#f1-1041036){ref-type="fig"}) have recently been identified as causing the severe skin disorder *erythrokeratodermia variabilis et progressiva 4* (EKVP4, OMIM617526), a condition characterized by neonatal onset of thick, scaly skin on the face and genitals, and milder erythematous palmoplantar scaling.^[@b8-1041036]^ This observation established a role for KDSR in the homeostasis of keratinization; however, it was unclear whether these cases had hematologic pathologies. A more recent study described four probands with EKVP4 caused by *KDSR* variants accompanied by severe thrombocytopenia and platelet dysfunction in infancy.^[@b9-1041036]^ A reduction in plasma S1P and surface-exposed ceramide in human platelets, as well as diminished ceramide levels in affected skin, were reported. Bone marrow (BM) morphology in one patient was normal and in a second patient demonstrated increased megakaryopoiesis. For this patient, a diagnosis of immune-mediated thrombocytopenia was made with no response to corticosteroid treatment and minimal response to splenectomy. No further exploration of the molecular mechanism underlying the thrombocytopenia was undertaken.^[@b9-1041036]^

![Reported *KDSR* variant genotypes and phenotypes in the context of 3-keto-dihydrosphingosine reductase (KDSR) structure and function. Protein and cDNA schematic adapted from Gupta *et al*.^[@b20-1041036]^ demonstrating location of known pathogenic KDSR variants with documented phenotypes in skin only (black), skin and platelets (red), and the novel variants reported in this manuscript in bold and underlined. Variants are linked by brackets where present in compound heterozygosity in an individual. Key structural elements of KDSR are illustrated: transmembrane anchors (blue, purple), the Rossman folds (red), and a highly conserved domain containing three putative catalytic sites (yellow). The novel p.Arg154Trp variant is within the catalytic domain.](1041036.fig1){#f1-1041036}

Here we provide evidence that in this pedigree, KDSR plays a fundamental role in megakaryopoiesis, cytoplasmic organization, and proplatelet formation. We describe a pedigree in which compound heterozygous variants in *KDSR* segregate with severe thrombocytopenia and minimal or no skin involvement. We report novel phenotypes of progressive juvenile myelofibrosis in the propositus, who is older, and anemia in both siblings. Broad metabolic profiling complemented by targeted mass spectrometry assays confirm KDSR hypofunction and suggest activation of an alternative, compensatory pathway *in vivo*. Depletion of kdsr in zebrafish and studies with CD34^+^ stem cell- and induced pluripotent stem cell (iPSC)-derived MK show cellular and biochemical signatures in common with those observed in our patients, showing the mechanism by which *KDSR* variants mediate thrombocytopenia.

Methods
=======

Recruitment and sequencing
--------------------------

Following informed, written consent (ethical study approval ML3580), the propositus was recruited to the Bleeding, thrombotic and Platelet Disorders (BPD) domain of the NIHR BioResource-Rare Diseases study (UK Research Ethics Committee 13/EE/0325, *<https://bioresource.nihr.ac.uk>*). Further details are provided in the *Online Supplementary Methods*.

Platelet studies
----------------

Aggregation and transmission electron microscopy (EM) studies were performed as described previously.^[@b10-1041036]^

Metabolic profiling
-------------------

Global metabolic profiling of plasma was performed by Metabolon Inc. (Durham, NC, USA) using the DiscoveryHD4 liquid chromatography tandem mass spectrometry (LC-MS/MS) platform, as previously described.^[@b11-1041036]^ Results of study participants were compared with 496 subjects between the ages of 4 and 55 years without thrombocytopenia. A separate LC-MS platform method, previously described,^[@b12-1041036],[@b13-1041036]^ was used for specific confirmation of the global sphingolipid profile. Further details are provided in the *Online Supplementary Methods*.

Stem cell differentiation assays
--------------------------------

CD34^+^ hematopoietic stem cells (HSC) were isolated by magnetic cell sorting (Miltenyi Biotec, Bergisch Gladback, Germany) from BM aspirates from the propositus (at 5 years of age) and an unrelated control, and from peripheral blood (PB) from the propositus (at 8.5 years of age), his affected sister (at 5 months of age), and an unrelated control.

In addition, expanded BM- and PM-derived^[@b12-1041036],[@b13-1041036]^ HSC at day 3 of differentiation were used for liquid MK cultures in two experiments. In the first experiment, HSC obtained from the BM of the propositus were differentiated in parallel to a control. For the second experiment, HSC obtained from the PB of the propositus and his affected sister were cultured in parallel with a different control. Details of the differentiation protocols, colony assays and statistical analysis of megakaryocyte (MK) immunostaining are provided in the *Online Supplementary Methods*.

Zebrafish analysis
------------------

Tg(cd41:EGF) embryos^[@b14-1041036]^ were injected at the one-cell stage with a *kdsr* ATG morpholino (MO) (5' ctcagaggacatgggtcaacctgat, Kdsr-MO) purchased from Gene Tools LLC (Philomath, OR, USA) or with buffer (control). Zebrafish kdsr has ZFIN accession number ZDB-GENE-040426-853. Thrombocyte formation was analyzed as described previously.^[@b15-1041036],[@b16-1041036]^ Immunoblots were developed with goat anti-GFP (Rockland) and anti-FVT1/KDSR (Clone H-149; Santa Cruz, CA, USA). All animal protocols were approved by the Ethical Committee of KU Leuven, Belgium.

Lentiviral reference 3-keto-dihydrosphingosine reductase transcript expression in induced pluripotent stem cells
----------------------------------------------------------------------------------------------------------------

Induced pluripotent stem cells (iPSC) were prepared by the Cambridge Biomedical Research Centre iPSC core laboratory as described in the *Online Supplementary Methods*. iPSC were transduced with the lentiviral vector to express the open reading frame (ORF) of *KDSR* (pLenti-EF1a-KDSR-myc-DDK-IRES-Puro, Origene) and the un-cloned destination vector PS10085 (Origene) to generate the reference transcript rescue line (Kresc) and empty vector control line (Kev), respectively. The ORF is identical to transcript ENST00000591902 (RefSeq accession n. NM_002035, Origene TrueClone cDNA cat. RC201153), which has the highest reported expression in MK.^[@b2-1041036]^ Details of lentiviral particle production, transduction and selection are given in the *Online Supplementary Methods*.

Forward programming to MK
-------------------------

Induced pluripotent stem cells were reprogrammed to MK (named iMK hereafter) using a protocol for generating MK described by Moreau *et al*.^[@b17-1041036]^ K^resc^ and K^ev^ iMK were generated in three independent experiments. Details of iMK reprogramming, immunophenotyping, the proplatelet assay, and RNA sequencing are given in the *Online Supplementary Methods*.

Results
=======

Clinical characteristics
------------------------

The 8-year old male propositus was born to healthy, unrelated parents of European ancestry ([Figure 2A](#f2-1041036){ref-type="fig"}). At 4 months of age he presented with a viral infection and was found to have a platelet count of 65×10^9^/L and mild normocytic, normochromic anemia with normal iron and hematinic levels ([Figure 2B](#f2-1041036){ref-type="fig"}, *Online Supplementary Table S1A and Online Supplementary Figure S1*). Subsequent complete blood counts showed on several occasions platelet counts \<100×10^9^/L accompanied by rectal and gingival bleeding, excessive ecchymosis, and recurrent epistaxis when platelet counts were \<10×10^9^/L. Possible skin involvement was limited to a slow-to-heal perianal wound following rectal manometry. Serial BM examinations revealed increased numbers of dysplastic MK and progressive severe myelofibrosis ([Figure 2C](#f2-1041036){ref-type="fig"}, *Online Supplementary Table S1B and Online Supplementary Figure S2*); despite this we observed significant fluctuation in the propositus's thrombocytopenia and normalization of the hemoglobin level over the course of his first decade ([Figure 2B](#f2-1041036){ref-type="fig"} and *Online Supplementary Table S1A*). The mechanism of the improvement is unclear, and occurred in the absence of identifiable environmental, therapeutic, or dietary interventions. Genetic analyses of BM DNA excluded known somatic mutations causal of myelodysplasia or primary myelofibrosis (*Online Supplementary Table S1B*). Light transmission platelet aggregation was normal with the exception of an attenuated response to stimulation with collagen at low dose (*Online Supplementary Table S1C*). The propositus's older brother and his parents were unaffected ([Figure 2A](#f2-1041036){ref-type="fig"}). His sister presented at birth with thrombocytopenia ([Figure 2A and B](#f2-1041036){ref-type="fig"}, and *Online Supplementary Table S1A*) and mild ichthyosis in her left axilla ([Figure 2D](#f2-1041036){ref-type="fig"}), but the skin symptoms resolved spontaneously over the first month. At 5 months of age she also developed persistent, normocytic, normochromic anemia ([Figure 2B](#f2-1041036){ref-type="fig"} and *Online Supplementary Table S1A*). Transmission EM analysis showed platelets of normal size ([Figure 2E](#f2-1041036){ref-type="fig"}). Delta (δ)-granules appeared diminished; however, it was not possible to count these accurately in the absence of whole-mount EM or a specific δ-granule marker (CD63 also stains lysosomal structures). There were no other marked ultrastructural abnormalities.

![Clinical characteristics associated with loss-of-function *KDSR* variants. (A) Pedigree and variants identified in *KDSR*. '+' denotes the major allele. The propositus and affected sibling, but not the healthy sibling, carry the missense variant 18:61018270 G\>A (p.Arg154Trp) and the nonsense variant 18:61006104 G\>A (p.Arg236\*). Co-segregation analysis demonstrated that the father carries the former and the mother the latter variant. (B) Serial blood counts are shown for the two affected siblings and a single value for the healthy brother. Fluctuating anemia and thrombocytopenia was observed, without evidence of neutropenia. (C) Bone marrow biopsy. (Left) Numerous dysplastic megakaryocytes made visible with linker for activation of T cell (LAT) staining are present. (Right) Marrow fibrosis with strong stromal reticulin staining. Magnification ×40. Further images can be found in the *Online Supplementary Appendix*. (D) The affected sibling was born during the course of this study and presented at birth with thrombocytopenia and mild ichthyosis in her left axilla. The skin symptoms improved spontaneously over the first month. (E) Platelets were examined by electron microscopy for an unrelated healthy control, the propositus, and the affected sibling. There were no marked morphological differences. Arrowed magnifications show delta granules. Magnification × 12,000.](1041036.fig2){#f2-1041036}

Pathogenic variants in *KDSR*
-----------------------------

The propositus and his affected sister carry a maternally inherited nonsense variant 18:61006104 G\>A (p.Arg236\*) and a paternally inherited missense variant 18:61018270 G\>A (p.Arg154Trp) in *KDSR* ([Figure 2A](#f2-1041036){ref-type="fig"}). The variants were confirmed by Sanger sequencing^[@b18-1041036],[@b19-1041036]^ (*Online Supplementary Figure S3*) and have minor allele frequencies in Europeans of 4.82×10^−5^ and 2.32×10^−4^, respectively. The missense variant p.Arg154Trp is localized in the catalytic domain of KDSR ([Figure 1](#f1-1041036){ref-type="fig"})^[@b20-1041036]^ and both are found in the most abundant *KDSR* transcripts in MK (*Online Supplementary Figure S4*).^[@b2-1041036]^ The nonsense variant is absent from two out of three major platelet transcripts, which is in keeping with minimal *de novo* sphingolipid synthesis in mature platelets (*Online Supplementary Figure S4*).^[@b7-1041036]^ The results of co-segregation study were concordant with an autosomal recessive mode of inheritance ([Figure 2A](#f2-1041036){ref-type="fig"}).

Sphingolipid profiles
---------------------

We reasoned that the variants would cause reduced enzymatic function, leading to a build-up of the substrate KDS ([Figure 3A](#f3-1041036){ref-type="fig"}). Indeed, global metabolic profiling showed KDS to be detectable in plasma from the propositus but not from the parents, the healthy sibling, or 496 unrelated controls ([Figure 3B](#f3-1041036){ref-type="fig"}). This finding was corroborated using a LC-MS platform for the selective measurement of specific sphingolipids, which confirmed that KDS was detectable in both patients and absent from the plasma of controls ([Figure 3C](#f3-1041036){ref-type="fig"} and *Online Supplementary Figure S5*). Interestingly, there was no reduction in downstream sphingolipids in the patients using either platform (*Online Supplementary Tables S2 and S3A*). In fact, global profiling showed levels of the KDSR product, DHS, were higher for the propositus than controls. These findings raise the hypothesis that KDSR hypofunction during *de novo* sphingolipid synthesis is compensated *in vivo* by alternative mechanisms, for example, by the recycling of relatively abundant sphingomyelins along a pathway that normally contributes little to free DHS production.^[@b4-1041036]^

![Metabolic profiling shows that the *KDSR* variants are associated with loss-of-function and downstream sphingolipid pathway compensation. (A) Simplified sphingolipid pathway highlighting the role of the 3-keto-dihydrosphingosine reductase (KDSR) enzyme in *de novo* synthesis (black arrows) and the generation of sphingolipid intermediates from the recycling of complex sphingolipids and sphingomyelins (green arrows). (B) Mass spectrometry using the Metabolon platform shows the major chromatographic peak of 3-keto-dihydrosphingosine (KDS) in the plasma of the propositus, but not of the unaffected pedigree members (shown) or the controls (*data not shown*). (C) KDSR hypofunction was confirmed in the propositus and affected sister using a second mass spectrometry platform for targeted sphingolipid profiling. The chromatogram shows that KDS was detected in the plasma from the propositus and his affected sister but not in the plasma from the healthy brother, parents (shown), and two controls (*data not shown*).](1041036.fig3){#f3-1041036}

Depletion of *kdsr* in zebrafish causes thrombocytopenia
--------------------------------------------------------

We explored the role of the enzyme on thrombocyte formation in zebrafish by MO-mediated depletion of the *kdsr* transcript in Tg(cd41:EGFP). As expected, this led to a reduction of the Kdsr protein level ([Figure 4A and B](#f4-1041036){ref-type="fig"}) and resulted in curved tails, which is a typical feature for embryos with thrombocytopenia (*Online Supplementary Figure S6*).^[@b15-1041036]^ The number of thrombocytes was inversely correlated with the dose of MO injected ([Figure 4C and D](#f4-1041036){ref-type="fig"}). Targeted sphingolipid profiling showed elevated and undetectable KDS in lysates from MO and control embryos, respectively ([Figure 4E](#f4-1041036){ref-type="fig"}). Similar to the results obtained with the propositus's plasma, dihydroceramides, ceramides, sphingomyelins and glycosphingolipids that are downstream of Kdsr were not significantly different between Kdsr-depleted and control fish (*Online Supplementary Table S3B*).

![*Kdsr* morpholino knockdown is associated with reduced thrombopoiesis in zebrafish. (A) Tg(cd41:EGF) embryos were injected with a kdsr ATG-MO (1000 μM) or with buffer (control). Embryos were lysed 72 hpf and used for immunoblotting. GFP and Kdsr proteins were reduced in the kdsr knockdown condition. Equal amounts (50 μg) were loaded (5 randomly selected embryos for each of the 4 conditions). Staining of Gapdh was used as loading control. (B) Quantification of immunoblot after normalization for Gapdh. Mean values are plotted and error bars show the standard deviation, analyzed by one-way ANOVA. (C) Quantification by flow cytometry of the number of GFP-labeled thrombocytes in Tg(cd41:EGFP) *Danio rerio* embryos at 72 hpf for kdsr-MO (800 or 1000 μM) or buffer (control) injected fish. Values are means and Standard Deviations as quantified for 10 randomly selected embryos for each condition, performed in triplicate. Results were analyzed by one-way ANOVA. (D) Grayscale stereo-microscope images (×20 original magnification) in the tail region at 72 hpf showed a reduced number of GFP-labeled thrombocytes (in white). (E) KDS levels in lysates from 72 hpf embryos (20/condition) for kdsr-MO (800 μM) or buffer (control) injected fish. KDS was detected in the lysates from the MO-injected embryos but not in the control-injected embryos.](1041036.fig4){#f4-1041036}

Impaired proplatelet formation in patient megakaryocytes
--------------------------------------------------------

CFU-GEMM cultures differentiated from bone marrow HSC of the propositus showed hyperproliferation of myeloid cells (*P*=0.001, *t*-test) with a reduced myeloid/erythroid ratio compared to the controls (*Online Supplementary Figure S7*). CFU-MK numbers were comparable to those of the control, although individual MK colonies were denser for the propositus, and liquid cultures showed an increased number of MK (*Online Supplementary Figure S8*). MK in control cultures formed proplatelets, whilst MK derived from both the propositus and the affected sister showed a strong reduction in proplatelet formation, despite similar levels of membrane budding and a higher number of CD41 and CD42 positive cells in propositus-derived cultures when compared with control MK ([Figure 5A](#f5-1041036){ref-type="fig"} and *Online Supplementary Figures S8-S10*). Patient-derived MK also showed extensive, abnormal formation of lamellipodia and reduced cell size (*P*=0.014, likelihood ratio test) ([Figure 5B and C](#f5-1041036){ref-type="fig"}).

![*KDSR* variants are associated with reduced proplatelet formation by megakaryocytes (MK). (A) Quantification of proplatelet formation by MK at day 11 of differentiation. On the left are the results of differentiation of bone marrow (BM)-derived hematopoietic stem cells (HSC) from the propositus and control. (Right) Results of differentiation of HSC obtained from the blood of the propositus, his affected sibling, and a second control. All MK with proplatelets and membrane budding were counted as positive. Values plotted are means and Standard Deviations (SD) as quantified on 20 images. Results were analyzed by the unpaired, two-tailed *t*-test. (B) MK at day 11 derived from BM HSC from the propositus and a control. MK are stained for the cytoskeletal marker F-actin (red) and lysosome and delta granule marker CD63 (green). MK from the propositus and affected sibling have irregular cytoskeletal structures with lamellipodia (arrows). Further images can be found in *Online Supplementary Figure S10*. (C) MK area was quantified by automated analysis. Modeling was performed using a linear mixed effects model and associated *P*-values were computed by a likelihood ratio test. MK from affected cases were smaller compared to unrelated controls (*P*=0.01473).](1041036.fig5){#f5-1041036}

The abnormal morphological, functional, and biochemical features of the propositus's induced pluripotent stem cells reprogrammed to megakaryocytes can be rescued
-----------------------------------------------------------------------------------------------------------------------------------------------------------------

To corroborate the atypical phenotypes of MK derived from the HSC, we transduced iPSC from the propositus with lentiviral vectors containing the reference *KDSR* ORF (K^resc^) or an inert control vector (K^ev^), and reprogrammed these cells to iMK (*Online Supplementary Figure S11A*). Analysis of the iMK RNA-seq results showed similar *KDSR* gene expression but the majority of sequencing reads in the rescued iMK carried the reference allele at Chr18:61018270 G\>A (p.Arg154Trp) (*Online Supplementary Figure S11B-D*). These findings are consistent with correction of the genetic defect without significant overexpression, and resulted in increased proplatelet formation compared with control iMK 4 h after seeding (*P*=0.047, *t*-test) ([Figure 6A-C](#f6-1041036){ref-type="fig"}). The observed iMK proplatelets were shorter and less branched than those observed following directed differentiation from stem cell cells, in keeping with published reports using this protocol.^[@b17-1041036]^ Upon microscopic inspection, the rescued iMK seemed larger than the non-rescued ones, which was confirmed to be significant by flow cytometry (*Online Supplementary Figure S11E*) and the increased proplatelet formation resulted by 24 h in little residual cytoplasm for the rescued *versus* the non-rescued iMK ([Figure 6C](#f6-1041036){ref-type="fig"}). At the biochemical level, the rescue resulted in a significant reduction in KDS levels (*P*=0.02, *t*-test) showing the effectiveness of the gene therapy approach in 'curing' the iMK from the propositus ([Figure 6D](#f6-1041036){ref-type="fig"}). Similar to findings in plasma and in zebrafish, there was no difference in DHS levels between the iMK with and without functional *KDSR* transcripts, indicating that the postulated, compensatory mechanism is also present in iMK. We searched the iMK transcriptome landscape for possible differences in the levels of transcripts of other key enzymes that regulate sphingolipid synthesis and recycling (the enzymes examined are as shown in [Figure 3A](#f3-1041036){ref-type="fig"}). This identified only *ASAH1* and *CERS6* transcripts to be down- and up-regulated respectively (posterior probabilities 0.610 and 0.774; log-fold change −0.67 and +0.70, respectively). These two enzymes regulate the ceramide-sphingosine ratio ([Figure 3A](#f3-1041036){ref-type="fig"} and *Online Supplementary Figure S12*), and in keeping with these findings, the rescued iMK showed higher sphingosine and lower ceramide levels ([Figure 6D](#f6-1041036){ref-type="fig"}).

![*KDSR* reference allele expression rescues ineffective proplatelet formation. Proplatelet formation by induced pluripotent stem cells reprogrammed to MK (iMK). One hundred percent of live MK plated for the proplatelet assay were CD41 positive and 75% were dual positive for CD41 and CD42 by flow cytometry (*Online Supplementary Figure S11A*). Cytoskeletal marker α-tubulin was stained with antibodies in green and nuclei were stained with DAPI in blue. Proplatelet formation was counted manually. Values shown were analyzed using the paired, two-tailed Student *t*-test plotted as means and standard deviations. \**P*\<0.05 was considered statistically significant. (A) The number of proplatelets formed at 4 hours (h) per proplatelet-forming MK (PPFMK) by the rescued and non-rescued iMK. The differences were significant at 4 h (*P*=0.047) but not at 24 h (*P*=0.20). (B) There was no significant difference in the number of PPFMK^−^ at 4 h between the two groups (7∙1% *vs*. 42∙4%; *P*=0.10), but at 24 h the rescued iMK showed less PPFMK (*P*=0.03). (C) Representative images from the proplatelet formation assay at 4 and 24 h. Proplatelets are indicated by white arrows. (Top left and right) Results at 4 h for rescued iMK show increased proplatelet formation. White scale bars indicate 10 μm. (Bottom left and right) Results at 24 h show little proplatelet formation for the rescued iMK, and residual cells are either fragmented into platelet-like particles, or consist of bare nuclei. (D) Metabolon mass spectrometry results for non-rescued and rescued iMK. The ion counts for KDS detection differed significantly between the non-rescued and non-rescued iMK (*P*=0.02). There was no difference in DHS level between the groups of samples but the levels of sphingosine and ceramide were lower and higher in the non-rescued *versus* rescued iMK, respectively. ns: not significant.](1041036.fig6){#f6-1041036}

Discussion
==========

Pathogenic mutations in *KDSR* have recently been associated with a recessively inherited syndrome of moderate-to-severe skin pathology and thrombocytopenia. We have described two novel *KDSR* mutations causing thrombocytopenia in the propositus and his infant sister, expanding the phenotypic spectrum of this recently identified Mendelian disorder from severe skin pathology with no apparent hematologic involvement to profound thrombocytopenia and moderate anemia with spontaneous improvement across the first decade, and almost imperceptible dermatological abnormalities. In the propositus, BM studies also showed the novel phenotype of severe juvenile myelofibrosis; however, the sister was too young to allow confirmation of this phenotype. The biochemical sphingolipid signatures of the plasma and patient-derived iMK confirmed the predicted reduction in function with elevated levels of its substrate, KDS. This is, as expected, from the combination of a variant encoding a premature stop codon and a hypomorphic allele involving a missense variant in the catalytic domain. Unexpectedly, downstream metabolites in the sphingolipid pathway, including DHS, ceramide, and sphingosine-1-phosphate, were not reduced in plasma, suggesting that KDSR hypofunction during *de novo* sphingolipid synthesis is compensated by an alternative pathway. One possible alternative pathway is the recycling of relatively abundant sphingomyelins; a pathway previously shown to contribute to production of downstream sphingolipids such as dihydroceramide, ceramide, and sphingosine, but considered to contribute little, if at all, to DHS production under normal conditions.^[@b21-1041036]^ Post-translational modifications to sphingolipid enzymes may also explain the metabolic profile, and further work is required to explore this possibility. Importantly, the profile of increased ceramide and reduced sphingosine in propositus-derived iMK compared with rescued iMK, and the consistent and potentially explanatory transcriptional dysregulation of enzymes *ASAH1* and *CERS6*, is in contrast to the limited sphingolipid quantitation undertaken in previous studies which showed that ceramide levels were reduced in affected skin and that platelet surface exposure of ceramide was impaired in individuals with hypo-functional *KDSR* variants.^[@b9-1041036]^

Our observation that MK lacking functional KDSR are hyperproliferative is consistent with earlier reports,^[@b9-1041036]^ but we expand on this characterization by showing the *ex vivo* generated patient MK to be smaller than controls and to be less effective in proplatelet formation. Proplatelets are pseudopodial projections of megakaryocyte cytoplasm, supported at their core by microtubular bundles that carry granules and other platelet cargo from the body of the megakaryocyte to the tip of the proplatelet.^[@b22-1041036]^ Aberrant size and proplatelet formation were not only observed in MK obtained by differentiation of primary HSC obtained from the two patients, but are also present in iMK generated by forward programming of iPSC derived from the propositus's fibroblasts. Taken together, we consider the ineffective platelet formation caused by the absence of KDSR to be the primary cause of the thrombocytopenia. Increased turnover because of a reduced platelet lifespan seems to be a less likely explanation because the immature platelet fraction was not significantly raised in the two patients compared with healthy controls (*data not shown*). We hypothesize that impaired platelet formation may, in turn, be caused by cytoskeletal disorganization and further experiments are required to explore this possibility. Pathogenic mutations in several other genes (e.g. *MYH9, ACTN1, FLNA, TUBB1, DIAPH1, TPM4*) encoding proteins with important functional roles in cytoskeletal reorganization and actin polymerization cause dominant forms of thrombocytopenia.^[@b23-1041036]^ However, these genetic disorders are characterized by enlarged platelets, and the mean volumes of the platelets of our patients are within the normal ranges for males and females, respectively.

The increased level of KDS in plasma was confirmed at the cellular level in iMK derived from the propositus. This increased level was normalized upon rescue of the propositus's iMK with a *KDSR* transcript carrying the reference allele. The correction of the biochemical defect was mirrored by a recovery of iMK size and improvement of their capacity to form proplatelets. To further support the central importance of KDSR in thrombopoiesis, we show that KDSR knockdown in a zebrafish model is associated with impaired thrombocyte formation. Similar approaches have identified multiple potential regulators of thrombopoiesis,^[@b24-1041036]^ though in isolation zebrafish studies these are limited by inherent differences in thrombopoiesis between mammals and fish, notably that zebrafish have nucleate thrombocytes rather than MK.

The marked, spontaneous improvement in the propositus's thrombocytopenia and anemia led to a reversal of the decision to treat the condition by HSC transplantation. The mechanism of this improvement is unclear, given the presence of progressive myelofibrosis and in the absence of clinical features to suggest significant extramedullary hemopoiesis such as splenomegaly. Recent studies have shown spontaneous improvement in blood counts in other inherited juvenile BM failure syndromes, most notably those associated with pathogenic variants in *SAMD9* or *SAMD9L*.^[@b25-1041036]^ In these cases, the improvement was attributed to the acquisition of corrective somatic mutations. Further longitudinal studies of individuals affected by pathogenic *KDSR* variants is essential to determine whether the clinical course described is representative, and whether a careful watch-and-wait approach rather than early intervention may be more appropriate in this genetically-defined subgroup of cases with inherited thrombocytopenia accompanied by BM failure.
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